# Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B

> **NCT07709520** · PHASE2 · RECRUITING · sponsor: **Fujian Akeylink Biotechnology Co., Ltd.** · enrollment: 80 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** GST-HG141
- **DRUG:** GST-HG131
- **DRUG:** GST-HG141 Placebo

## Key facts

- **NCT ID:** NCT07709520
- **Lead sponsor:** Fujian Akeylink Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-10
- **Primary completion:** 2026-10-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07709520

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07709520, "Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07709520. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*